A vulnerability in Palo Alto's PAN-OS is being exploited, warn the manufacturer and IT security authority CISA.
The Virtual OS Museum is a thing of beauty that's open to all ...
OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival ...
MacOS 27 Rumors: End of Intel Support, Smarter Siri, Tweaks to Liquid Glass and More ...
The spec sheet for the Primebook 2 Max looks almost too good to be true for its price. A 15.6-inch Full HD display, MediaTek ...
OS Therapies is expected to report today that its lead immunotherapy candidate, OST-HER2, has achieved a statistically significant overall survival benefit at 2.5 years in patients with fully resected ...
Perioperative pembrolizumab can improve OS when combined with neoadjuvant chemotherapy in patients with high risk, ...
The IGNYTE continues to show promising outcomes despite negative FDA decisions.
Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...
"ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies" was originally created and published by Clinical ...
With Innovent Biologics garnering buzz in the dealmaking space, Ta | Takeda and Innovent's long-term follow-up data from an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results